LA Private

Uncategorized

Develop Global finalises $100m loan facility with Trafigura

Develop Global (ASX:DVP) has completed the documentation for a loan facility of approximately A$100m with Trafigura, supporting the restart of its flagship Woodlawn copper-zinc mine in New South Wales. The facility, which includes a five-year offtake agreement, will fund the recommissioning of the mine and accelerate its return to production. Trafigura Group Pte Ltd, headquartered […]

Develop Global finalises $100m loan facility with Trafigura Read More »

Visioneering eyes ASX delisting

Visioneering Technologies (ASX:VTI) has announced plans to delist from the Australian Securities Exchange (ASX), with a vote on the proposal scheduled for a special meeting of stockholders on 10 January 2025. The company’s board believes the delisting is in the best interests of the company and its securityholders, citing challenges related to liquidity, valuation, and

Visioneering eyes ASX delisting Read More »

Integral Diagnostics clears ACCC hurdle for Capitol Health takeover

Integral Diagnostics (ASX:IDX), which operates diagnostic imaging services in Australia and New Zealand, has secured clearance from the Australian Competition and Consumer Commission (ACCC) for its proposed acquisition of Capitol Health (ASX:CAJ), subject to the divestment of a key clinic in Melton, Victoria. Capitol Health, headquartered in Melbourne, operates diagnostic imaging services across Victoria, Tasmania, South

Integral Diagnostics clears ACCC hurdle for Capitol Health takeover Read More »

Immutep launches Phase III trial in lung cancer

Immutep (ASX:IMM) has announced the initiation of its TACTI-004 Phase III clinical trial, which aims to evaluate the efficacy of its lead immunotherapy candidate, eftilagimod alfa (“efti”), in treating first-line metastatic non-small cell lung cancer (NSCLC). Efti will be used in combination with Merck’s Keytruda (pembrolizumab) and chemotherapy. This will be compared to the standard treatment of

Immutep launches Phase III trial in lung cancer Read More »

RBA holds at 4.35%, but “gaining some confidence” on inflation, Case for Feb cut is high

Dr Shane Oliver, Head of Investment Strategy & Chief Economist at AMP, discusses the cash rate. Key points: At its December meeting the RBA left the cash rate on hold at 4.35% as widely expected, leaving it unchanged for 13 months now. The RBA’s rates guidance pivoted to be more dovish though. It continues to

RBA holds at 4.35%, but “gaining some confidence” on inflation, Case for Feb cut is high Read More »

Funding win for Iluka, but shares tumble

Iluka Resources (ASX:ILU) has announced the successful conclusion of funding discussions with the Australian Government to support its $1.8bn Eneabba rare earths refinery in Western Australia. The refinery is designed to process both light and heavy rare earth oxides, positioning Iluka as a key player in the global rare earths market. Funding and project economics

Funding win for Iluka, but shares tumble Read More »